Introduction {#S0001}
============

Type 2 diabetes mellitus (T2DM) is a chronic and multifactorial metabolic disorder which is characterized by chronic hyperglycemia.[@CIT0001],[@CIT0002] World Health Organization-Diabetes country profiles stated 10.3% prevalence of diabetes in Iran in 2016.[@CIT0003] Haghdoost et al have been reported that the prevalence of type 2 diabetes appears higher in Iran than in other developing countries.[@CIT0004],[@CIT0005] T2DM and its accompanied serious complication including cardiovascular diseases, neuropathy and diabetic nephropathy are among the growing global health challenges.[@CIT0001] Several risk factors have been associated with the onset of T2DM, including family history, ethnicity, obesity, and abnormal serum lipid levels.[@CIT0006]--[@CIT0008]

Low-grade inflammation[@CIT0009],[@CIT0010] and innate immune response have been implicated as important pathogenic determinants of DM and late diabetic complications.[@CIT0011]--[@CIT0013] Among innate immune receptors, Toll-like receptor 4 (TLR4) is one of the key receptors forming an initial line of defense.[@CIT0014],[@CIT0015] The *TLR4* gene is Located on 9q33.1. TLR4 is distributed in many cells including macrophages, endothelial cells, brain, gut, liver, pancreas, muscle and adipose tissues.[@CIT0014] TLR4 is the receptor for structurally diverse molecules such as bacterial lipopolysaccharide (LPS),[@CIT0016] endogenous ligands; oxidized LDL, heat shock proteins (HSP) 60 and 70, fibrinogen, and fibronectin.[@CIT0017] Recent studies showed that *TLR4* up-regulation[@CIT0018] and activation have been associated with the inflammatory response in obesity and insulin resistance diabetic patients.[@CIT0019]--[@CIT0021] Moreover, there is a growing interest in the role of *TLR4* polymorphisms, especially 896A\>G and 1196C\>T in T2DM progression and its complication including nephropathy which had inconsistent results.[@CIT0021]--[@CIT0024] Due to the lack of information concerning the *TLR4* polymorphisms in Iranian T2DM patients and the higher prevalence of T2DM in Iranian population compared with other developing countries,[@CIT0004],[@CIT0005] we opted to explore the potential association of two *TLR4* 896A\>G and 1196C\>T polymorphisms with predisposition to T2DM.

Materials and Methods {#S0002}
=====================

Subjects {#S0002-S2001}
--------

A total of 100 T2DM patients (M: F = 27:73) (Mean age ± SD= 48.2 ± 7.14) and 100 age- and sex-matched healthy control subjects (M: F = 29:71) (Mean age ±SD = 47.3 ± 5.95) from Payambar Azam medical educational complex, Bandar Abbas, Hormozgan, Iran have been enrolled in this study. The written informed consent was obtained from each participant before enrollment in the study. Healthy subjects had been checked by the physician in the department of health center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. After 12 hrs of fasting, 7 mL of venous blood was taken from each participant. A normal fasting blood sugar level less than 100 mg/dL was referred for control without diabetes. The exclusion criteria were type 1 diabetes, severe peripheral vascular disease, and pregnancy. Nephropathy inclusion criteria have been determined based on American Diabetes Association (ADA).^25^ The persistent presence of elevated urinary albumin excretion (albuminuria), low-estimated glomerular filtration rate (eGFR), or other manifestations of kidney damage in persons with T2DM, were eligible for inclusion. All patients' clinical features were accredited by the specialist. The clinical characteristics of the samples are shown in [Table 1](#T0001){ref-type="table"}. Additional information for diabetic patients with or without nephropathy are shown in [[Supplementary Table 1](http://www.dovepress.com/get_supplementary_file.php?f=238942.docx)]{.ul}. All biochemical parameters (FBS, TG, Cholesterol, HDL and LDL) were measured using Pars Azmun kit (Pars Azmun, Tehran, Iran). The study protocol was approved by the ethics committee (HUMS.REC.1394.85) of Hormozgan University of Medical Sciences and the study was conducted in accordance with the Declaration of Helsinki. We calculated the sample size using the open-source epidemiologic statistics for public health software, version 3.01. The power of the study was estimated greater than 80% to detect significant effects with the odds ratio greater than 4 for the minor allele frequency (around 5--6%) of rs4986790.Table 1Clinical Characteristics of the Study SamplesCase (n=100)Control (n=100)PAge50 (42.5--53)46 (43--50)0.36Male/Female (n)29/7130/700.75Hypertension (n)37----BMI25 (23−29)24 (21--25)\<0.001Chol (mg/dL)166.8 ± 37.6191.3 ± 33\<0.001HDL (mg/dL)42 (36.5--46)35.5 (40--64)\<0.001LDL (mg/dL)88.5 (72--111.5)97 (81.5−105)0.54TG (mg/dL)149.5 (116.5--195.5)100 (71--133)\<0.001FBS (mg/dL)196.7 ± 74.197 ± 11.02\<0.001HbA1C (%)8.8 ± 2Not evaluated--OGTT (mg/dL)236.2 ± 98.4Not evaluated--T2DM duration(y)9.5 ± 5.3----Statin therapy (n)49----Nephropathy (n)11----Family history IHD (n)37----[^1][^2]

DNA Extraction and PCR Methods {#S0002-S2002}
------------------------------

DNA was extracted from blood cells using a genomic DNA isolation kit (PrimePrep, Genetbio, Korea). The concentration of extracted DNA was determined by Nanodrop spectrophotometer (NanoDrop 2000c, Thermo Fisher Scientific, USA). *TLR4* variants including: 896A\>G (GENE ID: rs4986790, HGVS:NC_000009.12:g.117713024A\>G) and 1196C\>T (GENE ID: rs4986790, HGVS:NC_000009.12:g.117713024A\>G) amplification was done by Single Specific Primer-Polymerase Chain Reaction (SSP-PCR) assay. Two independent reactions were performed for each sample. Specific primers[@CIT0026] are shown in [Table 2](#T0002){ref-type="table"}. HLA-DRB1 primers were used as an internal positive control. SSP-PCR mixture contained: 12.5 μL Taq 2x Master Mix Red (Ampliqon, Denmark), 2 μL of each primer pair (stock concentration of 10 μM), 1 μL of each internal control primer pair, 3 μL of sample DNA: (10--500 ng), and sterile double-distilled water to a final volume of 25 μL. The following touchdown PCR amplification condition was used for both of *TLR4* variants:Table 2The Sequence of Primers Used for SSCP-PCR Analysis of *TLR4* Gene PolymorphismsPrimer SequenceProduct Size (bp)*TLR4* 896A\>G. F5'-TTAGACTACTACCCCGATGA-3'307*TLR4* 896A\>G. F'5'-TTAGACTACTACCCCGATGG-3'*TLR4* 896A\>G. R5'-CACTTTGAGAACAGCAACC-3'*TLR4* 1196C\>T. F5'-CAAAGTGATTTCGGGACAAC-3'284*TLR4* 1196C\>T. F'5'-CAAAGTGATTTCGGGACAAT-3'*TLR4* 1196C\>T. R5'-ACTTCGAGACTGGACAAGC-3'HLA-DRB1.F5'-TGCCAAGTGGAGCACCCAA-3'796HLA-DRB1.R5'-GCATCTTGCTCTGTGCAGAT-3'

One cycle denaturation (95°C, 4') followed by 20 cycles (95°C, 30''; annealing at 65°C to 55°C, 5'' for each degree; and elongation at 72°C for 20''). The second step was repeated for 15 cycles (95°C, 10''; 55°C, 30''; 72°C, 20''). (Bio-Rad Laboratories, Inc.). The third step included the final elongation at 72°C for 5 min. The amplified fragments of 896A\>G and 1196C\>T were electrophoresed on 1.5% agarose (CinnaGen, Iran) gel, stained with GelRed dye (Biotium, Inc.) and photographed ([Figure 1A](#F0001){ref-type="fig"} and [B](#F0001){ref-type="fig"}).Figure 1SSP-PCR analysis of the (**A**) 1196C\>T (284 bp) and (**B**) 896A\>G (307 bp) variants in the T2DM patients. This person was heterozygous for both *TLR4*: 896A\>G and 1196C\>T.**Abbreviations:** SSP-PCR, sequence-specific primer PCR; T2DM, Type 2 diabetes mellitus.

Statistical Analysis {#S0003}
====================

Categorical data were presented as numbers and percentages and continuous variables as means ± SD. Intergroup comparisons were performed using the χ2-test for testing relationships between categorical variables. Based on "KS normality test" the results have been mentioned using; Mann--Whitney *U*-test for non-parametric and *t*-test for parametric variables. The related results are shown in each related table. Hardy--Weinberg equilibrium analyses were performed to compare observed and expected genotype frequencies using the chi-square test.

Odds ratios (ORs) were calculated and reported within the 95% confidence limits. P \< 0.05 was considered as statistically significant. Statistical analysis was performed using the Statistical Package for Social Sciences version 15.0 (SPSS Inc., Chicago, IL, USA). Linkage disequilibrium and haplotype analysis were done using software program SNPStats ([<https://www.snpstats.net/start.htm>]{.ul}).[@CIT0027] Logistic regression was carried out with adjustment for potential confounding covariates (age, sex, BMI) to obtain the odds ratio (OR) for risk of T2DM and clinicopathological aspects in both SNPs at 95% confidence intervals (CI).

Results {#S0004}
=======

Our study included 100 diabetic patients and 100 control subjects. Baseline characteristics of the cases and controls are shown in [Table 1](#T0001){ref-type="table"}. The frequency distribution of the *TLR4* 1196C\>T and *TLR4* 896A\>G were in accordance with Hardy--Weinberg equilibrium (P\> 0.05). The comparison of genotypes and allele frequencies of the 896A\>G and 1196C\>T polymorphisms in case and control groups are shown in [Table 3](#T0003){ref-type="table"}. No homozygous genotype was detected in our study for these two SNPs. Allele frequency and genotype distribution of both polymorphisms were not statistically significant between the case and control groups. No association was detected between these two SNPs and T2DM (P\> 0.05).Table 3Genotype and Allele Frequencies of 896A\>G (Rs4986790) and 1196C\>T (Rs4986791) of *TLR4* Gene Among 100 Diabetes Mellitus Cases and 100 Controls896A\>G\
(rs4986790)Case (n=100)Control (n=100)*χ*^2^POR (95% CI)Genotypes, n (%)AA81 (81%)88 (88%)1.870.170.78 (0.56--1.07)AG19 (19%)12 (12%)Alleles, n (%)A181(90%)188 (94%)1.710.190.8 (0.59--1.07)G19 (10%)12 (6%)**1196C\>T**\
**(rs4986791)**Genotypes, n (%)CC90 (90%)92 (92%)0.240.620.89 (0.57--1.38)CT10 (10%)8 (8%)Alleles, n (%)C190 (95%)192 (96%)0.230.620.89 (0.58--1.37)T10 (5%)8 (4%)[^3]

These two *TLR4* polymorphisms were in strong linkage disequilibrium (D= 0.0091, D'= 0.2202, r= 0.164, P= 0.001). Haplotype analysis showed no association with T2DM in our study (global P = 0.86; [Table 4](#T0004){ref-type="table"}).Table 4Haplotype Association with Response (n = 200)HaplotypeFrequencyCase (n=100)Control (n=100)OR (95% CI)OR (95% CI)AC0.891.001.00GC0.061.20 (0.33--4.27)5.66 (1.49--21.53)AT0.034.50 (0.70--29.00)2.38 (0.48--11.89)GT0.010.41 (0.01--24.88)0.00 (-Inf - Inf)[^4]

In 896A\>G position, the levels of FBS (171.2/142.3) and OGTT (163.5/109.7) have shown to be significantly increased in heterozygous genotype (AG) compared with AA subjects ([Table 5](#T0005){ref-type="table"}). Logistic regression showed the significant association between AG genotype and increased OGTT level (P= 0.048, OR= 1.003, 95% CI= (1.00--1.005)) ([[Supplementary Table 2](http://www.dovepress.com/get_supplementary_file.php?f=238942.docx)]{.ul}).Table 5Associations Between *896A\>G* Genotype and Clinicopathological VariablesTotal PopulationAA (n)AG (n)PBMI24 (22--26) (169)24 (22--29) (31)0.42FBS (mg/dL)109 (96 −184) (169)144 (105 −246) (31)0.04HDL (mg/dL)45 (37--56) (169)42 (39--46) (31)0.31LDL (mg/dL)89 (78--05) (169)98 (76 −109) (31)0.99TG (mg/dL)136.8 ± 73.5 (169)159 ± 64.1 (31)0.45Chol (mg/dL)180.4 ± 37.3 (169)179.8 ± 39.1 (31)0.98**In cases only**HbA1C (%)4.1 ± 0.3 (81)5.8 ± 0.8 (19)0.06OGTT (mg/dl)109.8 ±132.5 (81)163.5 ± 155 (19)0.04T2DM duration (y)9.7 ± 5.3 (76)8.6 ± 5.4 (15)0.45Hypertension (n)3160.58Family history IHD (n)2890.29Statin therapy (n)4180.63Nephropathy (n)1010.37[^5][^6]

For 1196C\>T; [Table 6](#T0006){ref-type="table"} shows the comparison of CC and CT genotypes with the clinicopathological aspects. After logistic regression ([[Supplementary Table 2](http://www.dovepress.com/get_supplementary_file.php?f=238942.docx)]{.ul}), a significant association was shown between diabetic nephropathy (DN) and CT genotype (P= 0.04, OR= 4.35, CI= (1.04--18.1)). Also, TG level has increased significantly in both T2DM and control subjects with a heterozygous genotype of 1196C\>T (P= 0.027, OR= 1.005, 95% CI= (1.001--1.01)).Table 6Associations Between *1196C\>T* Genotype and Clinicopathological VariablesTotal PopulationCC (n)CT(n)PBMI24 (22--26) (182)24.7 (22.5 −27) (18)0.79Chol (mg/dL)174.5 (151--202) (182)187.5 (148--210) (18)0.99HDL (mg/dL)45 (38--56) (182)42.5 (37--49) (18)0.29LDL (mg/dL)92 (78−107) (182)91 (76--107) (18)0.65TG (mg/dL)120 (86--169) (182)150 (82--193) (18)0.32FBS (mg/dL)109 (96--185) (182)136 (98--237) (18)0.35**In cases only**OGTT (mg/dl)116.5 ± 137.8 (90)134.1 ± 135.3 (10)0.86HbA1c (%)4.39 ± 4.6 (90)4.83 ± 4.5 (10)0.85T2DM duration (y)9 (6−12) (83)11 (7--15) (9)0.59Hypertension (n)3070.02Family history IHD (n)3340.83Statin therapy (n)4540.75Nephropathy (n)830.04[^7][^8]

Discussion {#S0005}
==========

To date, it is considered that the incidence of T2DM and its complication could be influenced by inflammation and immunity. Among inflammatory factors, TLR4 as an innate immune receptor can mediate inflammatory reactions.[@CIT0028] Several studies investigated the association between the *TLR4* 896A\>G and 1196C\>T polymorphisms and T2DM, but their results have been highly controversial.[@CIT0023] There are also limited studies on TLR4 in the inflammatory activation pathway and T2DM complications. In this regard, we focused on assessing *TLR4* polymorphisms influence on T2DM incidence and its clinicopathological aspects in Iranian population.

This study failed to detect any homozygous variant genotypes of 896A\>G and 1196C\>T polymorphisms in Iranian subjects. Also, we could not find any association between these two polymorphisms and T2DM susceptibility in our population. Our finding is consistent with several studies in the Asian population, which showed a lack of association between 896A\>G and 1196C\>T and T2DM[@CIT0029],[@CIT0030] and is inconsistent with other investigations which showed that these polymorphisms were protective against T2DM especially in Caucasian populations.[@CIT0014],[@CIT0031],[@CIT0032] Interestingly in our investigation, all carriers of variant alleles of these two SNPs are heterozygous and based on the Erridge et al study, they could express a functional TLR4 molecule.[@CIT0033] However, other studies mentioned that the TLR4 pathway could be affected by other molecules such as MyD88 or NF-κβ in diabetes and insulin control.[@CIT0034],[@CIT0035]

Previous investigations showed the metabolic syndrome role as a T2DM predictor.[@CIT0036] Regarding the impact of the *TLR4* polymorphism on major features of the metabolic syndrome.[@CIT0037] The statistical association was assessed between variant genotype of 1196C\>T and some clinicopathological features of T2DM such as TG, cholesterol, hypertension and BMI. Our findings are in line with Abbas et al study on rs5030717 and rs5030718 variants of *TLR4* in the risk of dyslipidemia in type 2 diabetes mellitus[@CIT0038] and Kolz study,[@CIT0039] which found a strong interaction between total cholesterol to high-density lipoprotein cholesterol (TC/HDL-C) and minor alleles of four *TLR4* variants (including 1196C\>T alleles), using a case-cohort design. They suggested that *TLR4* minor alleles of several variants might increase the risk for type 2 diabetes in subjects with high lipid profile via indirect effects.[@CIT0039] However, Illig et al[@CIT0029] did not find any difference in hypertension, BMI, waist circumference, or HDL/cholesterol levels in *TLR4* 896A\>G variant.

Here, statistics showed the impact of 1196C\>T variant on diabetic nephropathy (DN). Also, TG level has increased in subjects with heterozygous genotypes of 1196C\>T in the present study. These results might be in accordance with the association between increased serum lipid and TLR4 activation,[@CIT0040] *TLR4* polymorphisms involvement in the regulation of serum lipid metabolism[@CIT0041] and the role of disturbed lipid profiles, specifically TG in the pathogenesis of DN in different studies.[@CIT0042]--[@CIT0047] Although, the small number of nephropathy (11%) should not rule out here. Further investigation could advantage the present data in a case--control study involving DN cases and diabetes as controls.

The TLRs expression in glomerular endothelial cells[@CIT0048] and TLR4 role in tubular inflammation is well documented.[@CIT0028] Lin et al showed a higher expression of TLR4 in the renal tubules of human kidneys with DN compared with normal kidney and other kidney diseases.[@CIT0028] Apparently, high glucose induces TLR4 expression in human proximal tubular epithelial cells and results in the release of proinflammatory mediators[@CIT0028] and leukocyte infiltration in the renal tissue.[@CIT0049] Consistent with our results, Abbas et al compared the frequencies of the *TLR4* variants between nephropathy and dyslipidemia in T2DM patients, found a difference in the rs5030717 allele carriers.[@CIT0038] Kuwabara  et al study in diabetic mouse models elucidated that hyperlipidemia has a pivotal role in the progression of DN through the activation of TLR4/S100 calcium-binding protein A8 signaling cascade in glomeruli.[@CIT0050]

On the other hand, the mechanisms for higher triglyceride (TG) level in DN are affected by the duration of hyperglycemia and vascular endothelial damage, which in turn could be affected by TLR4 activation.[@CIT0047] This can also describe the association between AG genotype and increased OGTT level in this study. However, because of the limitations of our study, including the cross-sectional design which cannot establish causality, small sample size, and financial limitations, further investigations are recommended especially in DN patients compared with diabetics without nephropathy.

Conclusion {#S0006}
==========

In conclusion, the results represented here suggest that minor alleles of 1196C\>T and 896A\>G variants, although not directly associated with type 2 diabetes, but by involving in the dysregulation of serum lipid levels and hyperglycemia, might increase the risk of DN. To our knowledge, the current report is the first study investigating the *TLR4* variants in Iranian T2DM patients.
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[^1]: **Notes:** Parametric values are presented as mean ± standard deviation and non-parametric data are presented as median (Q1-Q3). Data were evaluated using *χ*^2^-test for sex; Mann--Whitney *U*-test for Age, BMI, HDL, LDL, and TG; *t*-test for the other variables. P \< 0.05 was considered as statistically significant.

[^2]: **Abbreviations:** OGTT, oral glucose tolerance test; IHD, ischemic heart disease.

[^3]: **Notes:** P \< 0.05 was considered as statistically significant.

[^4]: **Note:** Interaction p-value= 0.31; P \< 0.05 was considered as statistically significant.

[^5]: **Notes:** Parametric values are presented as mean ± standard deviation and non-parametric data are presented as median (Q1-Q3). Data were evaluated using χ2-test for Hypertension, IHD, Statin therapy and Nephropathy; Mann--Whitney *U*-test for Age, BMI, HDL, LDL, TG and FBS; *t*-test for the other variables. P \< 0.05 was considered as statistically significant.

[^6]: **Abbreviations:** OGTT, oral glucose tolerance test; IHD, ischemic heart disease.

[^7]: **Notes:** Parametric values are presented as mean ± standard deviation and non-parametric data are presented as median (Q1-Q3). Data were evaluated using χ2-test for Hypertension, IHD, Statin therapy and Nephropathy; Mann--Whitney *U*-test for BMI, Chol, HDL, LDL, TG, FBS and T2DM duration (y); *t*-test for the other variables. P \< 0.05 was considered as statistically significant.

[^8]: **Abbreviations:** OGTT, oral glucose tolerance test; IHD, ischemic heart disease.
